Carregant...
Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma
In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, pembrolizumab and ipilimumab, have been introduced into routine clinical practice for treating patients with several types of advanced cancer, including renal cell carcinoma (RCC). However, activation of the immune system again...
Guardat en:
| Publicat a: | Int Cancer Conf J |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Singapore
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947052/ https://ncbi.nlm.nih.gov/pubmed/33786286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-020-00458-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|